Walleye Trading
NBIX icon

Walleye Trading’s Neurocrine Biosciences NBIX Stock Holding History

Walleye Trading’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Hold
3,700
– – ﹤0.01% 2561
2026
Q1 		$487K Hold
3,700
– – ﹤0.01% 2608
2025
Q4 		$525K Buy
+3,700
New +$536K ﹤0.01% 2793
2025
Q1 		– Sell
-100
Closed -$13.7K – 4493
2024
Q4 		$13.7K Sell
100
-1,900
-95% -$235K ﹤0.01% 3989
2024
Q3 		$230K Buy
+2,000
New +$274K ﹤0.01% 2982
2024
Q2 		– Sell
-1,200
Closed -$166K – 4706
2024
Q1 		$166K Hold
1,200
– – ﹤0.01% 3531
2023
Q4 		$158K Buy
+1,200
New +$138K ﹤0.01% 3926
2022
Q1 		– Sell
-600
Closed -$51K – 5703
2021
Q4 		$51K Hold
600
– – ﹤0.01% 4671
2021
Q3 		$58K Sell
600
-400
-40% -$37.8K ﹤0.01% 4592
2021
Q2 		$97K Sell
1,000
-14,500
-94% -$1.39M ﹤0.01% 4392
2021
Q1 		$1.51M Buy
15,500
+14,200
+1,092% +$1.49M 0.01% 1574
2020
Q4 		$125K Sell
1,300
-13,900
-91% -$1.34M ﹤0.01% 3817
2020
Q3 		$1.46M Sell
15,200
-15,900
-51% -$1.84M 0.01% 1361
2020
Q2 		$3.79M Sell
31,100
-21,900
-41% -$2.42M 0.02% 672
2020
Q1 		$4.59M Buy
53,000
+40,100
+311% +$3.92M 0.04% 412
2019
Q4 		$1.39M Buy
12,900
+9,500
+279% +$995K 0.01% 1524
2019
Q3 		$306K Sell
3,400
-1,700
-33% -$159K ﹤0.01% 2569
2019
Q2 		$431K Sell
5,100
-27,500
-84% -$2.26M ﹤0.01% 2317
2019
Q1 		$2.87M Sell
32,600
-3,700
-10% -$309K 0.02% 813
2018
Q4 		$2.59M Buy
36,300
+24,300
+203% +$2.33M 0.02% 875
2018
Q3 		$1.48M Buy
12,000
+11,300
+1,614% +$1.28M 0.01% 1663
2018
Q2 		$69K Buy
+700
New +$62.7K ﹤0.01% 4168
2017
Q1 		– Sell
-200
Closed -$8K – 4998
2016
Q4 		$8K Buy
+200
New +$9.05K ﹤0.01% 4367

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Trading's NBIX Position: Q2 2026 in Review

Walleye Trading reduced its Neurocrine Biosciences (NBIX) stake by 29% in Q2 2026, selling an estimated $73.7K and leaving 1,200 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #3130.

Walleye Trading first reported a position in NBIX in Q2 2015 and has held it in 20 quarters since. The position peaked at $2.79M in Q1 2020. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Walleye Trading held 1,200 shares of Neurocrine Biosciences worth $202K as of Q2 2026.
  • Walleye Trading sold 497 Neurocrine Biosciences shares in Q2 2026, an estimated $73.7K.
  • Neurocrine Biosciences made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #3130 holding.
  • Walleye Trading first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 20 quarters since.
  • Walleye Trading's Neurocrine Biosciences position peaked at $2.79M in Q1 2020.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.